Peptide Decoding
New?New to peptides?Start here →
Decoding

NVG-291_Dosage, benefits & legal status

Also known as TAT-ISP, H'ISP, NVG291

Published November 19, 2026

A 35-residue peptide that tries to release the brake scar tissue puts on nerve regrowth.

Restore nerve function after spinal cord injury35-residue TAT-fused PTP sigma wedge mimetic (injected)Investigational
DoseNot published; once-daily injection for 12 weeks in trials
FrequencyOnce daily for 12 weeks (trial schedule)
RouteUnder the skin (subcutaneous)
StatusInvestigational
CycledA fixed 12-week daily course, then four weeks of observation

See how this dose compares across the library →

01

What is NVG-291?

Plain language first. The technical label stays, but it never stands alone.

Overview

A daily injection meant to let nerve fibers grow past scar tissue after spinal cord injury.

The technical version

A cell-penetrating peptide mimetic of the PTP sigma intracellular wedge domain, given subcutaneously to relieve chondroitin sulfate proteoglycan mediated inhibition of axonal regrowth.

What it's used for

An investigational injection for chronic spinal cord injury, in phase 3 and approved nowhere.

02

How does NVG-291 work?

What it does in the body, and where.

After a spinal cord injury the scar fills with chondroitin sulfate proteoglycans, a family of sugar-coated molecules. Those bind a receptor on the nerve fiber called protein tyrosine phosphatase sigma, and the message delivered is stop growing. NVG-291 is built to interrupt that message on the inside of the cell rather than trying to clear the scar away.

  1. 01
    The TAT tag gets it inside the cell
    The first ten residues, GRKKRRQRRR, are the cell-penetrating stretch of HIV's TAT protein. They are there for one reason: the target sits inside the cell, and a bare peptide would never reach it. The same tag is used across neuroscience for exactly this job.
  2. 02
    The rest is a copy of PTP sigma's own wedge
    The remaining 25 residues reproduce the wedge region of the receptor's intracellular side: a first helix, a four-residue turn, and a second helix. The peptide competes with the receptor's own wedge, which is how it modulates signaling rather than blocking the scar molecules from binding outside.
  3. 03
    In animals it produced regrowth and recovery
    The original work, published in Nature in 2015 by Jerry Silver's group at Case Western Reserve, reported recovery of locomotor, sensory and urinary function in rats given daily systemic injections after contusive cord injury. Later work found the mechanism includes increased cathepsin B secretion, which degrades the inhibitory matrix. Nearly all of that animal work used the rodent-matched version, not this one.
  4. 04
    In people the evidence is one small trial
    The phase 1b/2a chronic cohort showed a roughly threefold rise in normalized motor evoked potential amplitude in a hand muscle against placebo, which was statistically significant. The hand function score rose 3.7 points against 0.4 and did not reach significance. The phase 3 uses that hand function score as its primary endpoint.
Anatomical illustration highlighting the whole body
WHAT THIS COMPOUND ACTS ON:
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Chronic cervical motor-incomplete spinal cord injury, the phase 3 indicationtrial-protocol
  • Subacute spinal cord injury, a separate cohort in the phase 1b/2a trialtrial-protocol
  • Multiple sclerosis, stroke, traumatic brain injury and Alzheimer's disease, listed as development interests with no human trial on recordnone

The published record

Research index

1

Papers about NVG-291 · this compound only

Searched: NVG-291.

Left out: NVG-291-R (the rodent version, a different molecule one residue away); intracellular sigma peptide (in the original paper this names the rodent version, not this one); GRKKRRQRRRCDMAEHTERLKANDSLKLSQEYESI (the sequence, which does not appear in titles or abstracts); ISP (three letters that match many unrelated things); GRKKRRQRRR (a delivery tag shared by hundreds of unrelated peptides); TAT (that tag's short name, which matches many unrelated things); TAT-ISP (a catalog rendering built from two terms that are themselves too broad); PTPsigma (the receptor it acts on, with a large literature of its own); PTPRS (the receptor's gene name); CSPG (the scar molecules involved, with a very large literature of their own); chondroitin sulfate proteoglycan (the same molecules, written out); NVG-291-301 (the phase 3 study's code, not the compound); RESTORE (a trial name that is also an ordinary word); CONNECT SCI (another trial name); ILP (a related peptide from the same patent, a different molecule); cathepsin B (an enzyme involved downstream, with a large literature of its own); GRASSP (the name of a hand function test, not the compound).

3 papers tagged human · 0 not reviews or lab · 0 clinical trial publications

3 registered trials · none with posted results

Furthest stage reached: Phase 3, under way

Compare this against the whole library →

In animals0
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

NVG-291 vial rendering
Compound field notes

At a glance

Four things to know about NVG-291

01

Evidence

Investigational

02

Category

Healing and recovery

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

Not published; once-daily injection for 12 weeks in trials, once daily for 12 weeks (trial schedule). A fixed 12-week daily course, then four weeks of observation Trial dose

Both the phase 1b/2a and the phase 3 give daily injections for 12 weeks and then stop, watching for four more weeks. The company has reported that functional gains continued to increase during that off-treatment window, which is the argument for a defined course rather than ongoing dosing.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No pharmacokinetic figures have been released. Phase 1 single-ascending-dose and multiple-ascending-dose cohorts were run in healthy volunteers and the phase 3 lists pharmacokinetics among its objectives, so the data exist inside the program, but nothing has been published. The dosing schedule is once daily, which is consistent with a short-lived peptide, but that is an inference rather than a measurement.

You can compare this against the whole library to see where it sits.

06

How do I dose and price it?

Enter your vial and your dose. Pick a mix. We show the draw and the cost.

The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.

Your vial size (mg)
Enter the amount printed on your label.
What you paid per vial
$
Used for cost per dose only.
Your dose (mg)
Commonly referenced range: No milligram figure has been published. The company has not disclosed the dose used in either trial, and the phase 3 protocol summary describes it only as the dose from the earlier study. What is published is everything except the amount: a once-daily subcutaneous injection, given for 12 weeks, with cetirizine premedication, followed by a four-week observation period, alongside a standardized exercise or rehabilitative training protocol in both trials. The phase 3 adds an optional 12-week open-label extension. Because the dose is undisclosed, the calculator has nothing to draw, and any figure circulating for this peptide did not come from the sponsor or from a registry.No range

Choose your mix

mL water—units · —
Enter your own volume

Measuring the water1 mL = one full 100-unit syringe.

YOUR DRAW0 / 100 units
07

How do you store it?

Before mixing, and after.

Nothing to store: it is not sold anywhere.

NVG-291 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 54% charged residues, 23% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Any use outside a clinical trial, because there is no approved product, no published dose and no established safety margin
  • Spinal cord injury less than one year or more than ten years old, which is outside every population studied so far
  • Anyone treating a research-grade vial of the same sequence as equivalent to the trial drug

Stop and get help

These are emergencies. Seek care.
  • Any allergic reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • An injection site reaction that spreads, blisters or does not settle
  • New neurological symptoms such as worsening weakness or sensory change

Common effects

Expected, and usually mild.
  • Mild to moderate injection site reactions were the most common adverse events reported in the phase 1b/2a trial.
  • No treatment-related serious adverse events were reported in that study.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

What has happened recently

Investigational everywhere, approved nowhere. In the United States it holds Fast Track designation and, from November 12, 2026, Breakthrough Therapy designation for chronic traumatic cervical motor-incomplete spinal cord injury. In Europe it holds Orphan Drug designation for spinal cord injury. None of those is an approval. Breakthrough Therapy designation brings eligibility for priority review, rolling submission of a marketing application and more intensive FDA guidance; it is granted on preliminary clinical evidence suggesting substantial improvement over available therapy, and in this case the FDA granted it on review of data from the chronic cohort of a 24-person phase 1b/2a study whose manuscript was still being finalized as of November 2026. The registrational phase 3 was enrolling at the time of this review, with enrollment completion anticipated in the second half of 2027, so no approval decision is in front of any regulator.

Guides for this compound

Sources

  • Lang, Silver et al., Modulation of the proteoglycan receptor PTP sigma promotes recovery after spinal cord injury, Nature 518(7539):404(2015)
    The paper that designed this peptide, read for the sequences and the original animal result. The authors describe designing the Intracellular Sigma Peptide, a mimetic of the PTP sigma wedge with a TAT domain to allow membrane penetration. The methods list the peptides used: ISP as NH2-GRKKRRQRRRCDMAEHMERLKANDSLKLSQEYESI-NH2, the human-matched H'ISP as NH2-GRKKRRQRRRCDMAEHTERLKANDSLKLSQEYESI-NH2, and a TAT-free control as NH2-DMAEHMERLKANDSLKLSQEYESI-NH2. The human and rodent versions differ at one position, threonine against methionine. The reported result is recovery of locomotor, sensory and urinary function in rats after contusive spinal cord injury treated with daily systemic injection.
  • US9937242, Compositions and methods for inhibiting the activity of LAR family phosphatases, Case Western Reserve University(2018)
    The originating institution's patent, used to confirm the wedge sequence against the human protein independently of the Nature methods. It aligns the PTP sigma wedge domain across species and gives the human sequence from residue 1368 as PIPIADMAEHTERLKANDSLKLSQEYESI, with mouse and rat carrying methionine where human carries threonine. It names the first alpha helix of the human wedge as DMAEHTERLK, the turn as ANDS and the second alpha helix as LKLSQEYESI. Those three fragments, joined, are the non-TAT portion of NVG-291.
  • NervGen Pharma, NervGen Receives FDA Breakthrough Therapy Designation for NVG-291 in Chronic Spinal Cord Injury(2026)
    The company's own announcement of the designation, read as a company document and cited for the regulatory facts and the phase 3 eligibility. The FDA granted Breakthrough Therapy designation on November 12, 2026 for chronic traumatic cervical motor-incomplete spinal cord injury, based on its review of safety and efficacy data from the chronic cohort of the phase 1b/2a CONNECT SCI study. Eligible phase 3 participants are one to ten years after a traumatic spinal cord injury, with a motor level at C7 or higher on both sides and an ASIA Impairment Scale classification of C or D. They are randomized one to one to NVG-291 or placebo by once-daily subcutaneous injection for 12 weeks, followed by four weeks of observation, with an optional 12-week open-label extension planned. The company describes NVG-291 as a subcutaneously administered neuroreparative peptide targeting the inhibitory CSPG-PTP sigma pathway.
  • NervGen Pharma, CONNECT SCI Trial Chronic Cohort Update investor deck, June 3, 2025(2025)
    The sponsor's investor presentation of the chronic cohort results, read as a company document and cited for the two numbers that matter. A positive trend change from baseline in GRASSP quantitative prehension, an increase of 3.7 for NVG-291 against 0.4 for placebo, described as a trend rather than a significant difference. A statistically significant roughly threefold increase in normalized first dorsal interosseous motor evoked potential amplitude, P equals 0.0155. The design shown is daily subcutaneous injections for 12 weeks with rehabilitative training across 16 weeks, with assessments at baseline and weeks 2, 4, 8, 12 and 16. Safety is given as generally well tolerated with mild to moderate injection site reactions as the most common adverse events.
  • Registry record NCT05965700, NVG-291 in Spinal Cord Injury Subjects, linked but not read at source(2026)
    The phase 1b/2a registry record, read via a search-engine reproduction because ClinicalTrials.gov could not be opened during this review. It gives the study as interventional, phase 1 and phase 2, randomized, parallel, quadruple masked across participant, care provider, investigator and outcomes assessor, with an actual enrollment of 24. The experimental arm is NVG-291 administered by subcutaneous injection once daily for 12 weeks with cetirizine pretreatment, against a matching placebo. The chronic cohort required incomplete cervical spinal cord injury between one and ten years before randomization; the subacute cohort required 20 to 90 days.
  • Third-party copy of registry record NCT07799532, RESTORE phase 3(2026)
    The phase 3 registry record, read via a third-party reproduction for the same reason. The study is titled A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury, a randomized, double-blind, placebo-controlled multicenter phase 3 trial, with the internal code RESTORE and NVG-291-301. Enrollment is 150, randomized one to one, across 42 sites in two countries as of the October 22, 2026 registry update. The primary endpoint is change from baseline in the combined Graded and Redefined Assessment of Strength, Sensibility and Prehension quantitative prehension score. The study start date is recorded as actual on September 28, 2026, primary completion is estimated July 2027 and completion December 14, 2027, with topline guidance of the first half of 2028. The record was first submitted on August 18, 2026, which is what places this identifier numerically above trials registered earlier in the year.
  • NervGen Pharma, NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates, November 16, 2026(2026)
    The company's third-quarter update, read as a company document and cited for program status. Enrollment is ongoing in the phase 3 RESTORE study with continued activation of additional sites, including designated spinal cord injury Model Systems centers. The study is expected to enroll approximately 150 participants across the United States and Canada. The chief executive's quoted statement ties the FDA-aligned registrational design and the Breakthrough Therapy designation to preliminary clinical evidence from CONNECT SCI.
  • Streetwise Reports, NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury(2026)
    Independent trade coverage, read via a reproduction and used only for two facts the company release does not carry: that NVG-291 already holds FDA Fast Track and EMA Orphan Drug designations for spinal cord injury, and that the first phase 3 participant was dosed in October 2026. It also records that the hand function score trended positive in CONNECT SCI without reaching statistical significance, which matches the sponsor's own deck.

Beyond these, 4 records are indexed for this compound. Browse the records